Clinuvel Pharmaceuticals Limited (CLVLY) Q4 2025 Earnings Call Transcript

2025-08-28 09:19:15 ET

Clinuvel Pharmaceuticals Limited (CLVLY)

Q4 2025 Earnings Conference Call

August 28 2025, 04:00 AM ET

Company Participants

Malcolm Bull - Head of Australian Operations & Investor Relations

Peter Vaughan - Chief Financial Officer

Philippe Jacques Wolgen - MD & Director

Conference Call Participants

David Andrew Stanton - Jefferies LLC, Research Division

Mark Pachacz - Unidentified Company

Melissa Benson - Barrenjoey Markets Pty Limited, Research Division

Shane A. Storey - Wilsons Advisory and Stockbroking Limited, Research Division

Sinclair Currie - MA Moelis Australia Securities, Research Division

Thomas Wakim - Bell Potter Securities Limited, Research Division

Stella Mariss - Unidentified Company

Presentation

Stella Mariss

Hello, everyone. Thank you for joining CLINUVEL's investor webinar. I am Stella of Monsoon Communications. In today's webinar, CLINUVEL will share their financial year 2025 results and operational highlights for year ended on 30th June 2025. [Operator Instructions] I will now hand over to Malcolm Bull, Head of Investor Relations and Australian operations to conduct the proceedings.

Malcolm Bull

Thank you for the introduction, Stella, and also thanks to Monsoon Communications, who are facilitating yet another investor webinar for us. It's pleasing we have more than 190 participants on the line from around the world, and we thank you for your interest in CLINUVEL. I will say that some shareholders have told us they prefer a shorter 30-minute type webinar, but we have extended today's webinar at the request of several institutions to 45 minutes. And that reflects the number of questions that we've received as well....

Read the full article on Seeking Alpha

For further details see: